Skye Bioscience - SKYE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $22.00
  • Forecasted Upside: 82.42%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$12.06
▲ +0.1 (0.84%)

This chart shows the closing price for SKYE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Skye Bioscience Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SKYE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SKYE

Analyst Price Target is $22.00
▲ +82.42% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Skye Bioscience in the last 3 months. The average price target is $22.00, with a high forecast of $25.00 and a low forecast of $20.00. The average price target represents a 82.42% upside from the last price of $12.06.

This chart shows the closing price for SKYE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Skye Bioscience. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2024Cantor FitzgeraldInitiated CoverageOverweight$21.00Low
4/12/2024OppenheimerInitiated CoverageOutperform$25.00Low
3/14/2024Piper SandlerReiterated RatingOverweight ➝ Overweight$12.00 ➝ $20.00Low
2/5/2024Piper SandlerInitiated CoverageOverweight$12.00Low
(Data available from 5/27/2019 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
12/29/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/27/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/28/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/27/2024
  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
5/27/2024

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Skye Bioscience logo
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
Read More

Today's Range

Now: $12.06
Low: $11.56
High: $12.09

50 Day Range

MA: $12.57
Low: $11.32
High: $14.81

52 Week Range

Now: $12.06
Low: $1.44
High: $19.41

Volume

42,900 shs

Average Volume

37,125 shs

Market Capitalization

$338.52 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.74

Frequently Asked Questions

What sell-side analysts currently cover shares of Skye Bioscience?

The following Wall Street research analysts have issued reports on Skye Bioscience in the last twelve months: Cantor Fitzgerald, Oppenheimer Holdings Inc., and Piper Sandler.
View the latest analyst ratings for SKYE.

What is the current price target for Skye Bioscience?

3 Wall Street analysts have set twelve-month price targets for Skye Bioscience in the last year. Their average twelve-month price target is $22.00, suggesting a possible upside of 82.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting SKYE will reach $25.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $20.00 for Skye Bioscience in the next year.
View the latest price targets for SKYE.

What is the current consensus analyst rating for Skye Bioscience?

Skye Bioscience currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SKYE will outperform the market and that investors should add to their positions of Skye Bioscience.
View the latest ratings for SKYE.

What other companies compete with Skye Bioscience?

Other companies that are similar to Skye Bioscience include Precigen, AC Immune, Amarin, Nkarta and Silverback Therapeutics. Learn More about companies similar to Skye Bioscience.

How do I contact Skye Bioscience's investor relations team?

Skye Bioscience's physical mailing address is 11250 El Camino Real, Suite 100, San Diego, CA 92130, United States. The company's listed phone number is 858-410-0266 and its investor relations email address is [email protected]. The official website for Skye Bioscience is skyebioscience.com. Learn More about contacing Skye Bioscience investor relations.